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Abstract
antibiotic-resistant organisms causing both hospital-
and  community-acquired  complicated  skin  and  soft-
tissue infections (cSSTI) are increasingly reported. a
substantial medical and economical burden associated
with MRSa colonisation or infection has been docu-
mented. The number of currently available appropri-
ate antimicrobial agents is limited. good quality ran-
domised, controlled clinical trial data on antibiotic ef-
ficacy  and  safety  is  available  for  cSSTI  caused  by
MRSa.  linezolid,  tigecycline,  daptomycin  and  van-
comycin showed efficacy and safety in MRSa-caused
cSSTI. none of these drugs showed significant superi-
ority in terms of clinical cure and eradication rates.To
date, linezolid offers by far the greatest number of pa-
tients included in controlled trials with a strong ten-
dency  of  superiority  over  vancomycin  in  terms  of
eradication and clinical success.. 
Tigecycline is an alternative in polymicrobial infec-
tions except by diabetic foot infections. daptomycin
might be a treatment option for cases of cSSTI with
MRSa bacteremia. cSSTI caused by resistant gram-
negative bacteria are a matter of great concern. The
development  of  new  antibiotics  in  this  area  is  an 
urgent priority to avoid the risk of a postantibiotic 
era with no antimicrobial treatment options. an indi-
vidual approach for every single patient is mandatory
to evaluate the optimal antimicrobial treatment regi-
men.
InTRoduCTIon
Skin and soft tissue infections (SSTI) are amongst the
most  common  bacterial  infections  in  humans.  They
represent one of the most common indications for an-
tibiotic treatment and represent about 10% of hospital
admissions in the uS [1]. amongst the broad spec-
trum  of  skin  and  soft  tissue  infections  treatment  is
mainly delivered out of hospital. SSTI have a broad
range of aetiology, clinical manifestation and severity
[2, 3]. at one end of the spectrum the outcome may
be spontaneous resolution without antibiotics, but at
the other end it may present with sepsis with lethal
outcome. SSTI at 10% is the third most frequent focus
for severe sepsis or septic shock, after pneumonia (55-
60%) and abdominal infections (25%) [4]. 
This review aims to discuss the currently available
antibiotics  active  against  resistant  bacteria  (primarily
MRSa, VRE, ESbl-producing bacteria and carbapen-
em-resistant strains) in terms of mechanisms of action,
eradication rates and most important clinical outcome. 
ClaSSIfICaTIon of SkIn and SofT TISSuE
InfECTIonS
The classification of skin and soft tissue infections is
often confusing. Specific SSTI can be sub-categorised
according to the causative microbial agents, the main
tissue layer affected (i.e. skin, subcutis, fascia and mus-
cle) or according to clinical signs and symptoms. It is
to be differentiated, whether the infection is localised
or generalised. useful classifications are those which
differentiate SSTI according to urgency of surgical in-
tervention [5, 6]. Three categories can be differentiat-
ed:  Infections  treated  conservatively  (i.e.  erysipelas),
infections with the need for surgical intervention (i.e.
infective diabetic foot) and severe skin and soft tissue
infections that require urgent surgery (i.e. necrotising
fasciitis). 
another  classification,  provided  by  the  fda  and
frequently used for clinical trials differentiates between
uncomplicated and complicated SSTI, whereby the lat-
ter group is characterised by either deep soft tissue in-
volvement with signs of systemic sepsis, severe patient
immunosuppression or the necessity for major surgical
intervention [7]. 
The  key  to  successful  treatment  of  many  severe
soft tissue infections is based on early detection, ade-
quate calculated antibiotic treatment and prompt sur-
gical debridement.
aETIology and SPECTRuM of baCTERIa
SSTI can be caused by a multitude of bacterial agents.
The most important pathogenic agents are gram-pos-
itive bacteria, primarily S. aureus and group a strepto-
cocci. In recent studies more than 50% of all SSTI
were caused by staphylococcal or streptococcal species
[8-11]. The aetiological spectrum also includes entero-
cocci,  gram-negative  and  anaerobic  bacteria  with
necrotising, gangrenous infections and those close to
the trunk as well as bite injuries [12-14]. 
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crease in infections caused by pathogens that are resis-
tant to commonly used antimicrobial agents [15-17].
The emergence and spread of drug-resistant bacteria
has been facilitated by the selective pressure induced
by intensive use of antibiotics both in hospitalized and
out-patients.  a  growing  number  of  invasive  proce-
dures, performed in increasingly multi-morbid patient
populations and sometimes with inadequate infection
control  measures,  have  added  to  the  problem  [18].
other  factors  driving  the  process  include  greater
movement of people and the agricultural usage of an-
timicrobials [19].
This increase in infections is in contrast to a de-
crease in the number of novel antimicrobial therapeu-
tic  options  with  activity  against  drug-resistant
pathogens  [20].  The  antimicrobial  availability  Task
force of the Infectious diseases Society of america
(IdSa), recently identified vancomycin-resistant Ente-
rococcus faecium (VRE), methicillin-resistant Staphylo-
coccus  aureus (MRSa),  Acinetobacter  baumannii,
Pseudomonas aeruginosa, and extended spectrum β-lac-
tamase (ESbl)- producing Enterobacteriaceae as par-
ticularly problematic pathogens [21, 22]. 
an increased likelihood of drug-resistant organisms
as causative pathogens has been reported in both hos-
pital- and community-acquired complicated skin and
soft-tissue infections (SSTI) [23]. a substantial med-
ical  and  economical  burden  evoked  by  MRSa  colo-
nization or infection has been documented [24, 25]. In
the uS, community acquired MRSa (Ca-MRSa) is the
most frequent isolated bacteria in cSSTI [26]. Cases of
necrotizing cSSTI caused by Ca-MRSa are reported
[27]. The epidemiological shift towards drug-resistant
pathogens in the settings of complicated SSTI togeth-
er with the limited number of currently available ap-
propriate antimicrobial agents thus translates into rele-
vant problems in a population of seriously ill patients. 
lInEzolId
linezolid is an oxazolidinone antibiotic active against
many resistant and susceptible gram-positive organ-
isms (including MRSa, VRE and macrolide-resistant
streptococci [28]. linezolid has an oral and an intra-
venous  formulation  with  a  bioavailability  of  100%.
The tissue penetration into soft tissues in comparison
to serum concentrations is 105% [29]. linezolid has
been approved for the treatment of adult patients with
complicated  skin  and  skin  structure  infections  with
suspected or proven infections due to gram-positive
organisms including MRSa and VRE by the fda and
the EMa.
linezolid has been studied extensively in the treat-
ment of a broad range of skin infections [30-35]. a
recently published systematic review and meta-analysis
of  linezolid  versus  vancomycin  for  MRSa  skin  and
soft tissue infections [28] included four trials: three for
clinical outcome (n = 174) and three for microbiologi-
cal  outcome  (n  =  439).  for  clinical  outcomes  there
were non-significant trends in favour of linezolid (RR
0.34; 95% CI 0.04, 2.89; p = 0.32). for microbiological
outcome there was weak evidence of linezolid outper-
forming vancomycin (RR 0.55; 95% CI 0.30; p = 0.05)
[28]. In one study designed to evaluate the potential
for  linezolid  to  provide  superior  efficacy  to  van-
comycin in the treatment of cSSTI caused by known
or suspected MRSa, a subgroup analysis of patients
who had culture-proven MRSa indicated that linezolid
might  offer  advantages  over  vancomycin,  suggesting
the need for a definitive study in this subgroup [33].
Therefore, a phase 4 clinical trial was designed to bet-
ter define the relative efficacy of linezolid against ap-
propriately  dosed  vancomycin  for  the  treatment  of
cSSTI proven to be caused by MRSa. To address sev-
eral design limitations of the previous trials, only pa-
tients with documented MRSa infections were includ-
ed and the vancomycin dose was titrated according to
patient  weight,  changing  renal  function,  and  van-
comycin  troughs  [35].  240  patients  in  the  linezolid
group and 221 patients in the vancomycin group were
analyzed, representing the by far greatest number of
patients with proven cSSTI caused by MRSa that has
been investigated to date. The clinical success rate was
significantly higher in linezolid-treated patients in the
modified intent-to-treat population (p = 0.048). The
microbiological success rate was higher for linezolid at
the end of treatment (p<0.001) and was similar at the
end of the study (p = 0.127). 
linezolid  offers  the  possibility  of  early  switch  to
oral therapy and, consequently, early discharge, which
may be of possible economic advantage, particularly
in the field of cSSTI. This is discussed elsewhere in
this issue.
linezolid has been available for ten years now and
is well established as an effective agent in cSSTI [15].
a dose reduction is not necessary in renal insufficien-
cy. Its side effects of thrombocytopenia (2.2%) and
anaemia (4.8%) are considered mild, reversible and du-
ration  dependent  [36].  Mostly  in  patients  treated
longer than the recommended duration of 28 days, re-
versible and irreversible peripheral and optic neuropa-
thy, lactic acidosis and serotonin syndrome have been
observed [37].
daPToMyCIn
daptomycin, a fermentation product of Streptomyces
roseosporus,  is  a  cyclic  lipopeptide  antibiotic  with  a
rapid  concentration-dependent  bactericidal  activity
against gram-positive bacteria in vitro including resis-
tant and susceptible strains [38]. The good tissue pene-
tration into soft tissues is another pharmacokinetic ad-
vantage. It is only available as an intravenous infusion. 
daptomycin has been approved for the treatment
of adult patients with complicated skin and skin struc-
ture  infections  by  the  fda  and  the  EMa.  In  two
phase III studies 534 patients have been treated with
daptomycin in a dosage of 4 mg/kg body weight once
daily for cSSTI. The clinical success rate for dapto-
mycin was 83.4% in the daptomycin group and 84.2%
in  the  comparator  group  (vancomycin  1  g  bid  and
penicillinase-binding  semisynthetic  penicillin  4-12  g
daily, respectively). The clinical success rate in MRSa-
caused infections was 75% (21 of 28 patients) in the
daptomycin  group  versus  69%  in  the  vancomycin
group. The percentage of patients with a successful
therapy  (clinical  cure  or  improvement)  of  only  4-7
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(63%) than in the vancomycin group (33%, p<0,0001)
[10]. In a randomized trial with patients suffering from
diabetic foot infections (n = 103) the treatment suc-
cess with daptomycin and vancomycin was 71,4% and
69,4%,  respectively  [39].  a  sub-analysis  of  patients
with evidence of MRSa has not been performed Spe-
cific trials addressing the efficacy and safety of dapto-
mycin in cSSTI proven to be caused by MRSa have
not been published yet. daptomycin showed good ef-
ficacy in the treatment of MRSa caused bacteremia
and / or infective endocarditis [40, 41]. Consequently,
daptomycin  has  been  recommended  as  a  possible
treatment  option  in  patients  with  cSSTI  caused  by
MRSa and a high risk or evidence for bacteremia [80].  
daptomycin is safe and well tolerated when admin-
istered  once  daily  according  to  on  label  dosage  (4
mg/kg body weight). The most frequent documented
side effects are of gastrointestinal origin (nausea, vom-
iting)  [10,  41].  In  higher  dosages  (6  mg/kg  body
weight) an increasing number of CPk elevations has
been  observed.  This  led  to  discontinuation  of  the
drug in some cases [41]. a dose reduction is not nec-
essary  in  renal  insufficiency.  In  comparison  to  van-
comycin,  daptomycin  was  associated  with  a  signifi-
cantly lower rate of nephrotoxicity (6,7% daptomycin
versus 18,1% vancomycin) [10, 41]. Its activity is inde-
pendent of the cytochrome p450 system. 
TIgECyClInE
Tigecycline is a novel glycylcycline antibiotic for sys-
temic use with broad-spectrum activity against aerobic
and facultative gram-positive and gram-negative bac-
teria and anaerobic bacteria [42]. Tigecycline is active
in  vitro  against  antibiotic-resistant  bacteria  such  as
VRE  (Enterococcus  faecalis and  E.  faecium),  MRSa,
ESbl-producing  gram-negative  and  carbapenem-re-
sistant bacteria [43, 44].
Tigecycline has been approved for the treatment of
adult patients with complicated skin and skin structure
infections by the fda and the EMa. The patient pop-
ulation in the 2 phase III studies evaluating the use of
tigecycline  in  cSSTI  presented  with  a  comparatively
low mean (aPaCHE) II score [9]. 
There is a lack of data on the treatment of severely
ill  patients  from  the  pivotal  trials  with  tigecycline.
available data on the use of tigecycline in severely ill
patients are mostly from retrospective analyses [45, 46]
or studies with a focus on identified pathogens rather
than the clinical picture [47-49]. 
Recently, data from prospective controlled trials on
the efficacy and safety of tigecycline in the treatment
of  severely  ill  patients  with  complicated  infections
were published [50, 51]. In one monocenter study in-
cluding 207 patients (mean aPaCHE II score: 21) 8%
of the patients treated with tigecycline were found to
suffer from cSSTI. The clinical success rate was 76%
[50].  In  a  prospective  observational  multicenter  trial
including 656 patients (mean aPaCHE II score: 19)
with  tigecycline  mono-  or  combination  therapy,  102
patients (15,5%) were defined as cSSTI. The spectrum
of  isolated  bacteria  frequently  included  resistant  or-
ganisms (MRSa: 65% of all S. aureus isolates, VRE:
14% of all enterococcal isolates, ESbl E. coli: 28%).
The clinical success rate was 82% [51]. 
although  in  vitro  activity  has  been  proven  [52],
Tigecycline failed to reach non- inferiority over the
comparator  substance  in  a  trial  with  patients 
suffering from diabetic foot infection (data on file).
Therefore, the drug is to date not approved for this
indication.  Tigecycline  is  in  general  a  well  tolerated
substance.  frequently  observed  side  effects  are  of
gastrointestinal  origin  (nausea,  vomiting).  Cases  of
acute  pancreatitis  following  the  administration  of
tigecycline have been observed [53]. a trend towards
a higher mortality rates in patients treated with tigecy-
cline in comparison to control subjects has been no-
ticed [54]. The data from the pivotal trial with tigecy-
cline  versus  vancomycin-aztreonam  in  cSSTI 
revealed a non-significant difference in mortality of
0.7% [9]. 
VanCoMyCIn
Vancomycin,  a  glycopeptide,  has  bactericidal  activity
against  gram-positive  organisms  in  vitro  including
multiple-resistant  (MRSa)  and  susceptible  (MSSa)
strains. It is only available as an intravenous infusion.
The tissue penetration into soft tissue is poor (Table 1)
[55]. It has been the gold standard for the treatment of
MRSa infections for many years when no other drugs
were available. 
Vancomycin has been the comparator substance for
numerous clinical trials of new substances (linezolid,
daptomycin,  tigecycline)  for  the  treatment  of  cSSTI
suspected or proven to be caused by MRSa (Table 2).
despite the pharmacokinetic weaknesses and the poor
clinical  results  from  other  MRSa  infections  treated
with vancomycin, none of these drugs showed signifi-
cant  superiority  over  vancomycin  regarding  clinical
cure and eradication rates [8, 9, 10, 35]. This probably
reflects the paramount importance of surgical source
control in many cSSTI, which in part masks the real
clinical value of an antibiotic. Moreover, the study de-
sign (non-inferiority) and the study population (many
studies did not meet the fda criteria for complicated
SSTI) may have prevented detection of significant dif-
ferences [56]. Consequently, vancomycin is still an op-
tion  in  mild  to  moderate  cSSTI  caused  by  MRSa
(Table 3). 
due to poor clinical results in treatment of MSSa
and MRSa pneumonia and sepsis, there is increasing
concern about the use of vancomycin in serious infec-
tions [57]. These data have led to the recommendation
of  combination  with  other  drugs  (primarily  ri-
fampicin),  on  the  assumption  that  a  combination
might improve clinical outcome. However, the combi-
nation of vancomycin and rifampicin is not based on
controlled clinical data. Potential side effects are inter-
action with the cytochrome P450 system and frequent
development of resistance against rifampicin [58].   
There have been efforts for optimising the dosage
of  vancomycin.  a  trough  level  of  >15  μg/ml  has
been recommended as desirable [59]. However, in a re-
cently  published  trial  comparing  linezolid  and  van-
comycin for the treatment of cSSTI caused by MRSa,
the vancomycin dose was titrated according to patient
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troughs. There was no correlation found between van-
comycin  trough  levels  (0-5,  >5-10;  >10-15,  >15
μg/ml) and clinical or microbiological outcome [35].
Moreover,  with  high  (>15  ﾵg/ml)  trough  levels  the
risk for nephrotoxicity is substantially increasing [60].
When vancomycin is combined with aminoglycosides,
the creatinine rise may be as high as 35% [61]. finally,
unfavourable  clinical  outcomes  under  vancomycin
therapy have been shown to be referred to an increas-
ing resistance with a minimum inhibitory concentra-
tion (MIC) >1 ﾵg/ml [62]. unfortunately, many clini-
cians are not provided with MIC data of vancomycin
when  clinical  decisions  have  to  be  made.  Taking  all
these  issues  together,  it  appears  to  be  a  reasonable 
approach to dispense with vancomycin as a first-line
treatment for severe cSSTI and to use it only if other
treatment options are not tolerated or available (Table
3). 
anTIbIoTICS WITHouT daTa fRoM
ConTRollEd TRIalS
(TRIMETHoPRIM-SulfaMETHoXazolE,
RIfaMPICIn, foSfoMyCIn, ClIndaMyCIn,
QuInoPRISTIn/dalfoPRISTIn)
The good tissue penetration, the oral formulation and
the  low  costs  make  trimethoprim-sulfamethoxazole
(TMP-SMX) an attractive alternative to newer more
expensive drugs or those which require intravenous
application  (glycopeptides,  daptomycin,  tigecycline).
In  vitro  TMP-SMX  is  rapidly  bactericidal  against
MRSa and has been shown to have a better in vitro
bactericidal  activity  against  MRSa  than  linezolid, 
rifampicin, clindamycin or minocycline [63]. unfortu-
nately  we  were  unable  to  find  prospective  studies 
of TMP-SMX in treating patients with cSSTI caused
by  MRSa.  The  only  available  randomized  double-
blinded  trial  compared  TMP-SMX  (1g  twice  daily)
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Table 1. general characteristics of antibiotics with activity against MRSa.
antibiotic Route Mechanism  tissue penetration  In vitro Spectrum  dose adjustment 
of action (% of serum  of activity against necessary in renal
concentration) resistant bacteria impairment
linezolid i.v., oral bacteriostatic 105 % MRSa, VRE no
Tigecycline i.v. bacteriostatic 91% MRSa, VRE, ESbl, CRb no
daptomycin i.v. bactericidal 68,4% MRSa, (VRE) no
Vancomycin i.v. bactericidal 8-10% MRSa yes
TMP-SMX i.v., oral bactericidal n.a. MRSa yes
Rifampicin i.v., oral bactericidal n.a. MRSa yes
fosfomycin i.v. bactericidal 91% MRSa yes
Clindamycin i.v., oral bacteriostatic 95% MRSa no 
Quino./dalfo i.v. bactericidal n.a. MRSa, (VRE) yes
CRb = carbapenem resistant bacteria
TMP-SMX = trimethoprim-sulfamethoxazole
(VRE) daptomycin = increasing number of treatment failures and emergence of resistance under therapy for VRE
(VRE) quinopristin/dalfopristin = no activity against E. faecium
Table 2. assessment of antibiotics with activity against MRSa according to clinical data.
antibiotic Randomized  Eradication Eradication  reference Toxicity in on  daily cost
controlled studies rate (%) rate (n) label use
linezolid yes 85,4 205/240 [35] + +++
Tigecycline yes 78,1 25/32 [9] + +++
daptomycin yes 75 21/28 [10] + +++
Vancomycin yes 68,8 152/221 [35] ++ ++
TMP-SMX no 53 26/49 [64] ++
Rifampicin no 53 26/49 [64] ++
fosfomycin no n.a. n.a. n.a. ++
Clindamycin no n.a. n.a. n.a. ++
Quino./dalfo no n.a. n.a. n.a. +++ +++
Toxicity: + = mild to moderate , ++ = moderate to severe , +++ = severe 
daily cost: + = 5-25 Euro/day, ++ = 25-50 Euro/day, +++ ≥ 50 Euro/day
TMP-SMX = trimethoprim-sulfamethoxazole
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biocin  (500  mg  twice  daily)  and  rifampicin  300  mg
twice daily) for MRSa-decolonization [64]. The eradi-
cation rate was 53% (TMP-SMX plus rifampicin) and
67% (novobiocin plus rifampicin), respectively. dur-
ing therapy, 14% (7/49 patients) of the TMP-SMX
group  developed  emergence  of  resistance  to  ri-
fampicin. 
fosfomycin  has  an  in  vitro  bactericidal  activity
against MRSa. The pharmacokinetic properties of the
drug (excellent tissue penetration) make it appear rea-
sonable to use fosfomycin for MRSa caused cSSTI,
particularly in combination with other substances [65-
67]. To the best of our knowledge there are only limit-
ed controlled clinical data on the use of fosfomycin in
cSSTI  caused  by  MRSa  from  a  compassionate  use
study [67, 68]. unsolved questions of dosage, a rapid
development of resistance under treatment and poten-
tial  severe  side  effects  (liver  failure)  are  matters  of
concern [69]. 
Quinopristin/dalfopristin (Q/d) is a semisynthetic
mixture of two streptogramin antibiotics. both sub-
stances  have  a  bacteriostatic  mechansim  of  action
against  gram-positive  bacteria,  but  in  combination
bactericidal activity can be observed [70]. It is inactive
against Enterococcus faecalis. We could not find any
controlled data regarding the use of Q/d for MRSa-
caused  cSSTI.  There  are  only  retrospective  data  for
the treatment of VRE infections [71]. The substantial
side effect profile (severe myalgia, severe venous irrita-
tion, rapid emergence of resistance, interaction with
cytochrome  P450  system)  have  led  to  the  abandon-
ment of the Q/d [72].
Clindamycin may be an alternative in MRSa-caused
cSSTI, although resistance to this agent is a problem.
The penetration of the drug into soft tissues, that can
be  administered  both  i.v.  and  orally,  is  high.  Clin-
damycin is an effective inhibitor of protein biosynthe-
sis, making it like linezolid to a valuable drug particu-
larly in cases of Ca-MRSa [73]. data from controlled
trials do not exist to date, but efficacy has been shown
in case series [74]. The toxicity profile of clindamycin
is tolerable. The possible development of Clostridium
difficile-associated colitis needs close clinical observa-
tion under therapy. 
The lack of evidence from controlled studies with
regard to efficacy and safety is a substantial flaw of 
all of the above mentioned compounds. Many of the
randomized  trials,  that  have  been  performed  for 
approval  of  substances  in  cSSTI,  were  criticized 
not having met all of the fda criteria for compli  -
cated  SSTI  [7,  56].  nevertheless,  as  seen  before 
the background of data from pivotal trials for line  -
zolid,  tigecycline,  daptomycin  and  vancomycin 
[8-10,  35],  the  administration  of  drugs  without   
evidence from controlled trials needs to be consid-
ered  very  carefully,  particularly  under  medicolegal 
aspects.
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Table 3. Clinical decision-making for the choice of antibiotic with activity against MRSa according to the severity of disease.
severity of infection characteristics setting preferred route substances
mild - limited local signs  outpatient oral TMP-SMX ﾱ rifampicin
- no systemic signs  clindamycin*◊
- no surgery required  linezolid*
- patient stable
moderate - marked local signs hospitalized,  initially i.v. linezolid*
- systemic signs measurable general ward tigecycline#
- surgery required daptomycin
- patient stable  vancomycin
sequential oral  linezolid*
treatment clindamycin* ◊
TMP-SMX ﾱ rifampicin
severe - massive local and/or  inpatient,  initially i.v. linezolid*
systemic signs intensive daptomycin
- surgery required care [bacteremia]
- patient unstable tigecycline #
[polymicrobial inf.]
(vancomycin)
sequential oral linezolid*
treatment clindamycin*◊
TMP-SMXﾱ rifampicin
* preferred in cMRSa infections
# not indicated in diabetic foot infections
◊ = if susceptible
TMP-SMX = trimethoprim-sulfamethoxazole
(vancomycin) = to be used only if other drugs are not tolerated or not available
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The differentiation between colonisation and infection
in cSSTI is of paramount clinical importance for the
initiation of an antimicrobial treatment. The clinical
differentiation between colonisation and infection can
be extremely difficult even for experienced physicians.
on one hand the recognition of an infection can be
complicated  in  a  case  of  a  diabetic  foot  syndrome
when classical local and systemic signs of infection are
disguised by an ischemic component of the disease.
on the other hand a substantial immunosuppression
(e.g. leucopenia during chemotherapy) might be a rea-
son for the initiation of an antibiotic treatment even
in case of colonisation. In a Cochrane review the re-
sults of a treatment of MRSa colonization with topi-
cal or systemic administration of several agents in im-
munocompetent  patients  has  been  investigated.  Six
randomized studies with 384 patients were included.
The authors did not find superiority for any drug over
placebo  except  for  the  nasal  decolonisation  with
mupirocin [75]. development of resistance and toxici-
ty  were  significantly  more  frequent  in  the  verum
group. Therefore, antibiotic treatment of colonisation
of skin and soft tissues with MRSa is only indicated
in rare cases.
IS THERE a ClInICally RElEVanT
dIffEREnCE bETWEEn baCTERIoSTaTIC and
baCTERICIdal dRugS?
The general characteristics of anti-MRSa substances
are listed in Table 1. In Table 2 the controlled clinical
data of the compounds are listed. from the analyzed
drugs, vancomycin, daptomycin, TMP-SMP, Q/d, fos-
fomycin and rifampicin are described as bactericidal,
whereas linezolid, clindamycin and tigecycline as bac-
teriostatic.  bacteriostatic  and  bactericidal  categoriza-
tions in clinical practice are not absolute and can lead
to false assumptions concerning antimicrobial therapy,
especially if major pharmacokinetic and pharmacody-
namic parameters like tissue penetration and plasma
protein binding are ignored. The bacteriostatic agent
linezolid  has  shown  non-significant  superiority  over
the bactericidal vancomycin in every controlled study
for the treatment of cSSTI caused by MRSa [8, 31,
35], whereas the rapidly bactericidal drug daptomycin
has failed to reach superiority over comparator sub-
stances in cSSTI [10]. It is important to distinguish mi-
crobiological  and  clinical  definitions.  To  date,  there
has not been found any significant advantage for bac-
tericidal agents in the treatment of cSSTI. The ulti-
mate guide to treatment of any infection must be clini-
cal outcome [76].  
TREaTMEnT RECoMMEndaTIonS foR
anTIMICRobIal THERaPy
The adequate empirical antibiotic treatment in cSSTI
caused by MRSa has been shown to be a significant
predictor  for  treatment  success  [77].  The  antibiotic
treatment of cSSTI is well reviewed in the published
guidelines  [78-81].  any  clinical  guideline  for  antimi-
crobial  treatment  of  (MRSa-caused)  cSSTI  should
follow the clinical presentation of the affected patient.
differentiation between outpatient treatment (prefer-
ably with oral agents), and hospitalised patients with
or without sepsis (primarily intravenously, followed by
oral treatment if possible) is set out in Table 3. al-
though concerns remain about the quality of random-
ized trials in cSSTI [56], linezolid, tigecycline, dapto-
mycin and vancomycin have proven efficacy and safety
in  MRSa-caused  cSSTI  [8-10,  35].  none  of  these
drugs showed significant superiority regarding clinical
cure and eradication rates. To date, linezolid offers by
far the greatest number of patients included in trials
with cSSTI caused by MRSa and showed a strong ten-
dency  of  superiority  over  vancomycin  in  terms  of
clinical  success  rates  and  eradication  rates  [34,  35].
due  to  its  pharmacokinetic  unreliability,  its  toxicity
and increasing resistance (“MIC-creep”) and relatively
poor results in the treatment of severely ill patients,
the administration of vancomycin should be restricted
only to cases of moderate severity of infection or if
other treatment options are not tolerated or available
[57]. 
In cSSTI caused by MRSa it is useful to differenti-
ate between monomicrobial and polymicrobial infec-
tions [80]. In those cases, agents merely active against
gram-positive  bacteria  (linezolid,  daptomycin,  van-
comycin) have to be combined with drugs showing ac-
tivity against gram-negative and anaerobic organisms.
Tigecycline  is  an  alternative  in  polymicrobial  infec-
tions  excluding  diabetic  foot  infections  [9].  dapto-
mycin appears to be a treatment option for cases of
cSSTI and MRSa bacteremia [10, 80].
cSSTI caused by VRE have not been investigated
under conditions of controlled trials. Treatment rec-
ommendations (linezolid, tigecycline) are based on in
vitro data [8, 9] as well as personal experience and are
summarized in Table 4 modified according to [81].
In cSSTI caused by resistant gram-negative bacte-
ria  (primarily  ESbl-producing  or  carbapenem-resis-
tant  strains),  carbapenems  (ESbl)  and  tigecycline
(ESbl and carbapenem-resistant bacteria) are the only
available in vitro effective drugs with a tolerable toxici-
ty (Table 4). However, evidence from controlled trials
is  almost  completely  missing  [50,  51].  Colistin  has
been  shown  to  be  associated  with  poorer  survival
compared to controls, a significantly higher rate of re-
nal toxicity and a high rate of subsequent infections
caused by Proteus spp. [82]. 
as long as more than one therapeutic alternative is
available,  the  application  of  antibiotic  diversity  ap-
pears to be a very useful tool in order to reduce the
antibiotic selective pressure on any substance as a part
of an antibiotic stewardship program [15, 17].
despite  national  and  international  recommenda-
tions and guidelines, it is important to stress that local
epidemiology  and  antibiotic  resistance  patterns  are
important in determining empirical antibacterial ther-
apy.
Treatment  duration  can  usually  be  confined  to  7
days, providing that the patient and wound have im-
proved clinically and blood inflammatory signs (CRP,
leucocytes) have substantially reduced. However, con-
trolled  clinical  data  regarding  the  duration  of  treat-
ment in cSSTI are not available to date. 
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• The treatment of cSSTI caused by resistant bacteria
relies on a combination of surgical and antimicro-
bial treatment. good quality controlled clinical data
for  the  efficacy  and  safety  is  only  available  for
MRSa-caused cSSTI.
• linezolid, tigecycline, daptomycin and vancomycin
have  shown  efficacy  and  safety  in  MRSa-caused
cSSTI. none of these drugs showed significant su-
periority  regarding  clinical  cure  and  eradication
rates.  linezolid  offers  to  date  by  far  the  greatest
number  of  patients  included  in  controlled  trials
with  a  strong  tendency  of  superiority  over  van-
comycin.
• Tigecycline is an alternative in polymicrobial infec-
tions excluding diabetic foot infections. 
• daptomycin  is  an  effective  treatment  option  for
cases of cSSTI and MRSa bacteremia. 
• due to its pharmacokinetic shortfalls, the toxicity
and the increasing resistance and poor clinical re-
sults in the treatment of severe infections, the ad-
ministration  of  vancomycin  should  be  restricted
only to cases of mild or moderate severity of infec-
tion or if other treatment options are not tolerated
or available. 
• cSSTI  caused  by  resistant  gram-negative  bacteria
(mainly  ESbl-producing  or  carbapenem-resistant
strains) are a matter of great concern. Carbapenems
(ESbl) and tigecycline (ESbl and carbapenem-re-
sistant  bacteria)  are  the  only  available  effective
drugs with a tolerable toxicity. 
• The development of new antibiotics in this area is
urgently required in order to avoid a postantibiotic
era without any antimicrobial treatment option.
• an individual approach for every patient is essential
to establish an optimal treatment regimen. as long
as more than one therapeutic alternative is available,
the application of antibiotic diversity is a useful tool
in order to reduce the antibiotic selective pressure
on particular agent.
Acknowledgements: This article is dedicated to my dear friend
kamal.
Transparency  declarations: CE  has  received  speaker
honoraria from Pfizer, Wyeth, bayer, MSd and no-
vartis  and  has  participated  on  advisory  boards  for
Wyeth and Pfizer. Md has received speaker honoraria
and served on advisory boards for Pfizer, Wyeth, bay-
er, Janssen- Cilag, novartis.
REfEREnCES
1. dinubile  MJ,  lipsky  ba.  Complicated  infections  of
skin and skin structures: when the infections is more
than  skin  deep.  J  antimicrob  Chemother  2004;  53
(Suppl 2):37-50
2. nichols Rl, florman S. Clinical presentation of soft
tissue infections and surgical site infections. Clin Inf
dis 2001; 33; S83-93
3. lipsky ba. Cellulitis, erysipelas and necrotizing soft tis-
sue infections. best Practice of Medicine. 
http://www.bestpracticeofmedicine.com 2002
4. Engel C., brunkhorst fM, bone Hg et al. Epidemiolo-
gy of sepsis in germany: results from a national pro  -
spective multicenter study. Intensive Care Med 2007;
33:606-18
5. kingston d, Seal dV. Current hypotheses for synergis-
tic microbial gangrene. br J Surg 1990; 77: 260
6. Eckmann C. Severe skin and soft tissue infections. In-
tensivmed 2009;46: 480-485
7. Center  for  drud  Evaluation  and  Research  (CdER).
uncomplicated  and  complicated  skin  and  skin-struc-
ture  infections  –  developing  antimicribial  drugs  for
treatment. 
http://www.fda.gov/cder/guidance/2566dft.pdf 1998
8. Weigelt J, Itani k et al. linezolid versus vancomycin in
the treatment of complicated skin and soft tissue infec-
tions. antimicrob agents Chemother 2005; 49: 2260-
2266
9. Ellis-grosse EJ, babinchak T et al. The efficacy and
safety of tigecycline in the treatment of skin and skin-
structure infections: results of 2 double-blind phase 3
comparison studies with vancomycin-aztreonam. Clin
Infect dis 2005; 41: S341-353
10. arbeit Rd, Maki d et al. The safety and efficacy of
daptomycin fort he treatment of complicated skin and
skin-structure infections. Clin Inf dis 2004; 38: 1673-
1681
11. Wilson SE, oﾴRiordan W, et al. Telavancin versus van-
comycin  fort  he  treatment  of  complicated  skin  and
skin-structure infections associated with surgical proce-
dures. am J Surg 2009; 197: 791-796
12. Jones ME et al. Epidemiology and antibiotic suscepti-
bility of bacteria causing skin and soft tissue infections
in the uSa and Europe: a guide to appropriate antimi-
crobial therapy. Int J antimicrob agents 2003: 406-419
13. giordano  P  et  al.  Sequential  intravenous/oral  moxi-
floxacin versus intravenous piperacillin-tazobactam fol-
lowed by oral amoxicillin-clavulanate for the treatment
of complicated skin and skin structure infection. Int J
antimicrob agents 2005; 26(5):357-65
14. Moet gJ et al. Contemporary causes of skin and soft
tissue infections in north america, latin america, and
Europe: report from the SEnTRy antimicrobial Sur-
veillance Program (1998-2004). diagn Microbiol Infect
dis 2007; 57(1): 7-13
15. dryden M. Complicated skin and soft tissue infection. J
antimicrob Chemother. 2010;65 (S3):iii35-44
16. Wilcox MH. The tide of antimicrobial resistance and 
selection.  Int  J  antimicrob  agents  2009;  34  S3:  S6-
10.
EuRoPEan JouRnal of MEdICal RESEaRCH 560 november 30, 2010
Table 4. antibiotics against VRE, ESbl and carbapenem-re-
sistant bacteria in cSSTI.
Organism Antibiotic Duration
VRE linezolid 7 days
Tigecycline
ESbl Carbapenem group 1 and 2 7 days
Tigecycline
fosfomycin+
Colistin
Carbapenem Tigecycline 7 days
resistant bac. Colistin
+ = combination therapy necessary
6 Eckmann##_Umbruchvorlage  23.11.10  11:50  Seite 56017. nathwani d. new antibiotics for the management of
complicated skin and soft tissue infections: are they any
better? Int J antimicrob agents 2009; 34: S24-9.
18. Wilcox MH. Tigecycline and the need for a new broad-
spectrum antibiotic class. Surg Infect (larchmt) 2006;
7: 69-80.
19. Hawkey PM, Jones aM. The changing epidemiology of
resistance. J antimicrob Chemother 2009; 64: i3-10.
20. boucher HW, Talbot gH, bradley JS et al. bad bugs,
no drugs: no ESkaPE! an update from the Infectious
diseases Society of america. Clin Infect dis 2009; 48:
1-12.
21. Talbot gH, bradley J, Edwards JE, Jr. et al. bad bugs
need  drugs:  an  update  on  the  development  pipeline
from the antimicrobial availability Task force of the
Infectious diseases Society of america. Clin Infect dis
2006; 42: 657-68.
22. Rice lb. federal funding for the study of antimicrobial
resistance in nosocomial pathogens: no ESkaPE. J In-
fect dis 2008; 197: 1079-81.
23. dryden MS. Skin and soft tissue infection: microbiolo-
gy and epidemiology. Int J antimicrob agents 2009; 34
Suppl 1: S2-7.
24. Chaberny If, ziesing S, Mattner f, barwolff S et al.
The burden of MRSa in four german university hospi-
tals. Int J Hyg Environ Health 2005;208:447-453
25. Engemann JJ, Carmeli y, Cosgrove SE, fowler Vg et
al.  adverse  clinical  and  economic  outcomes  attribut-
able  to  methicillin  resistance  among  patients  with
Staphylococcus aureus surgical site infection. Clin In-
fect dis 2003;36:592-598
26. Moran gJ, krishnadasan a, gorwitz RJ, fosheim gE
et  al.  Methicillin-resistant  Staphylococcus  aureus
among patients in the emergency department. n Eng J
Med 2006;355:666-674
27. young lM, Price CS. Community-acquired methicillin-
resistant Staphylococcus aureus emerging as important
cause of necrotizing fasciitis. Surg Infect 2008;9:469-
474
28. dodds TJ, Hawke CI. linezolid versus vancomycin for
MRSa  skin  and  soft  tissue  infections.  anz  J  Surg
2009;79:629-635
29. Moellering RC. linezolid: the first oxazolidinone an-
timicrobial. ann Intern Med 2003;138:135-142
30. Stevens dl, Smith lg, bruss Jb et al. and the linezol-
id Skin and Soft Tissue Infections Study group. Ran-
domized comparison of linezolid (Pnu-100766) versus
oxacillin-dicloxacillin for the treatment of complicated
skin  and  soft  tissue  infections.  antimicrob  agents
Chemother 2000;44:3408-3413
31. Stevens dl, Herr d, lampris H et al. linezolid versus
vancomycin  for  the  treatment  of  methicillin-resistant
Staphylococcus  aureus  infections.  Clin  Infect  dis
2002;34:1481-1490
32. lipsky ba, Itani k, norden C: and the linezolid dia-
betic foot Infections Study group. Treating foot infec-
tions  in  diabetic  patients:  a  randomized,  multicenter,
open-label  trial  of  linezolid  versus  ampicillin-sulbac-
tam/amoxicillin-clavulanate.  Clin  Infect  dis  2004;38:
17-24
33. Weigelt J, Itani k, Stevens dl et al. linezolid eradi-
cates MRSa better than vancomycin from surgical-site
infections. am J Surg 2004;188:760-766
34. Sharpe Jn, Shively EH, Polk HC Jr. Clinical and eco-
nomic  outcomes  of  oral  linezolid  versus  IV  van-
comycin in the treatment of MRSa-complicated, low-
er-extremity skin and soft-tissue infections caused by
methicillin-resistant Staphylococcus aureus. am J Surg
2005;189:425-428 
35. Itani kMf, dryden MS, bhattacharyya H, kunkel MJ
et  al.  Efficacy  and  safety  of  linezolid  versus 
vancomycin for the treatment of complicated skin and
soft-tissue  infections  proven  to  be  caused  by  methi-
cillin-resistant  Staphylococcus  aureus.  am  J  Surg 
2010;
36. gerson Sl; kaplan Sl, bruss Jb et al. Hematological
effects of linezolid: summary of clinical evidence. an-
timicrob agents Chemother 2002;46:2723-2726
37. narita M, Tsuji bT, yu Vl. linezolid-associated pe-
ripheral and optic neuropathy, lactic acidosi, and sero-
tonine  syndrome.  Pharmacotherapy  2007;27:1189-
97
38. Steenbergen Jn, alder J, Thorne gM, Tally fC. dap-
tomycin: a lipopeptide antibiotic for the treatment of
serious gram-positive infections. J antimicrob Chemo  -
ther 2005;55:283-288
39. lipsky ba, Stoutenburgh u. daptomycin for treating
infected diabetic foot ulcers: evidence from a random-
ized, controlled trial comparing daptomycin with van-
comycin or semi-synthetic penicillins for complicated
skin and soft tissue infections. J antimicrob Chemoth-
er 2005;55:240-245
40. lamp k et al. daptomycin for the treatment of Staphy-
lococcus aureus bacteremia. Clin Res Cardiol 2007;96:
447-448 
41. fowler  Vg,  boucher  HW,  Corey  gR  et  al.  dapto-
mycin versus standard therapy for bacteremia and en-
docarditis caused by Staphylococcus aureus. n Eng J
Med 2006;355: 653-665
42. nicolau dP. Management of complicated infections in
the era of antimicrobial resistance: the role of tigecy-
cline.  Expert  opin  Pharmacother  2009;  10:  1213-
22.
43. kresken M, leitner E, brauers J et al. Susceptibility of
common aerobic pathogens to tigecycline: results of a
surveillance study in germany. Eur J Clin Microbiol In-
fect dis 2009; 28: 83-90.
44. kresken M, leitner E, Seifert H et al. Susceptibility of
clinical  isolates  of  frequently  encountered  bacterial
species to tigecycline one year after the introduction of
this new class of antibiotics: results of the second mul-
ticentre  surveillance  trial  in  germany  (g-TEST  II,
2007). Eur J Clin Microbiol Infect dis 2009; 28: 1007-
11.
45. Swoboda S, ober M, Hainer C et al. Tigecycline for the
treatment of patients with severe sepsis or septic shock:
a drug use evaluation in a surgical intensive care unit. J
antimicrob Chemother 2008; 61: 729-33.
46. Chemaly Rf, Hanmod SS, Jiang y et al. Tigecycline use
in cancer patients with serious infections: a report on
110  cases  from  a  single  institution.  Medicine  (balti-
more) 2009; 88: 211-20.
47. Vasilev k, Reshedko g, orasan R et al. a Phase 3,
open-label, non-comparative study of tigecycline in the
treatment  of  patients  with  selected  serious  infections
due  to  resistant  gram-negative  organisms  including
Enterobacter  species,  acinetobacter  baumannii  and
klebsiella pneumoniae. J antimicrob Chemother 2008;
62 Suppl 1: i29-40.
48. Poulakou g, kontopidou fV, Paramythiotou E et al.
Tigecycline in the treatment of infections from multi-
drug resistant gram-negative pathogens. J Infect 2009;
58: 273-84.
49. gordon nC, Wareham dW. a review of clinical and
microbiological outcomes following treatment of infec-
tions involving multidrug-resistant acinetobacter bau-
mannii with tigecycline. J antimicrob Chemother 2009;
63: 775-80.
EuRoPEan JouRnal of MEdICal RESEaRCH november 30, 2010 8, 2010 561
6 Eckmann##_Umbruchvorlage  23.11.10  11:50  Seite 56150. bassetti M, nicolini l, Repetto E, Rghi E, del bono V,
Viscoli C. Tigecycline use in derious mosocomial infec-
tions:  a  drug  use  evaluation.  bMC  Infect  dis  2010;
10:287
51. Eckmann  C,  Heizmann  WR,  von  Eiff  C,  leitner  E,
l￶schmann Pa, bodmann kf. Prospective, non-inter-
ventional  multicentre  trial  of  tigecycline  in  the  treat-
ment of severely ill patients. Chemother J 2010;19:165-
166
52. Petersen PJ, Ruzin a, Tuckman M, Jones CH, In vitro
activity of tigecycline against patient isolates collected
during  phase  3  clinical  trials  for  diabetic  foot  infec-
tions.  diagn  Microbiol  Infect  dis  2010;66:407-
418h
53. Hung Wy, kogelman l, Volpe g et al. Tigecycline-in-
duced acute pancreatitis: case report and literature re-
view. Int J antimicrob agents 2009; 34: 486-9.
54. http://www.fda.gov/drugs/drugSafety/ucm224370.htm 
55. daschner fd, frank u, kuemmel S, Schmidt-Eisen-
lohr E et al. Pharmacokinetics of vancomycin in serum
and tissue of patients undergoing open-heart surgery. J
antimicrob Chemother 1987;19:802-4
56. McClaine RJ, Husted Tl, Hebbeler-Clark S, Solomkin
JS. Meta-anaysis of trials evaluating parenteral antim-
crobial therapy for skin and soft tissue infections. Clin
Infect dis 2010;50:1120-1126
57. gonzalez  C,  Rubio  M,  Romero-Vivas  J  et  al.  bac-
teremic  pneumonia  due  to  Staphylococcus  aureus:  a
comparicon  of  disease  caused  by  methicillin-resistant
and methicillin-susceptible organisms. Clin Infect dis
1999;29:1171-1177
58. deresinski S. Vancomycin in combination with other
antibiotics for the treatment of serious methicillin-re-
sistant  Staphylococcus  aureus  infections.  Clin  Infect
dis 2009;49:1072-1090
59. Rybak M, lomaestro b, Rotschafer JC, Moellering R et
al. Therapeutic monitoring of vancomycin in adult pa-
tients: a consensus review of the american Society of
Health-System  Pharmacists,  the  Infectious  diseases
Society of america, and the Society of Infectious dis-
eases  Pharmacists.  am  J  Health-Syst  Pharm  2009;
66:82-98
60. Hermsen Ed, Hanson M, Sankaranarayanan J, Stoner
Ja et al. Clinical outcomes and nephrotoxicity associat-
ed  with  vancomycin  trough  concentrations  during
treatment of deep-seated infections. Expert opin drug
Saf 2010;9:9-14
61. farber bf. Retrospective study of the toxicity of prepa-
rations of vancomycin from 1974 to 1981. antimicrob
agents Chemother 1983;23:138-141
62. Sakoulas g, Moise-broder Pa, Schentag J, forrest a et
al. Relationship of MIC and bactericidal activity to effi-
cacy of vancomycin for treatment of methicillin-resis-
tant Staphylococcus aureus bacteremia. J Clin Microbi-
ol 2004;42:2398-2402
63. kaka aS, Rueda aM, Shelburne Sa, Hulten k, Hamill
RJ, Musher dM. bactericidal activity of orally available
agents against methicillin-resistant Staphylococcus au-
reus. J antimicrob Chemother 2006;58:680-683
64. Walsh TJ, Standiford HC, Reboli aC, John Jf et al.
Randomized double-blinded trial of rifampicin with ei-
ther  novobiocin  or  trimethoprim-sulfamethoxazole
against methicillin-resistant Staphylococcus aureus col-
onization:  prevention  of  antimicrobial  resistance  and
effect of host factors on outcome. antimicrob agents
Chemother 1993;37:1334-1342
65. Stengel, d; gorzer, E; Schintler, M; legat, fJ; amann,
W; Pieber, T; Ekkernkamp, a; graninger, W. Second-
line treatment of limb-threatening diabetic foot infec-
tions with intravenous fosfomycin. J Chemother 2005;
17(5): 527-35.
66. falagas,  ME;  giannopoulou,  kP;  kokolakis,  gn;
Rafailidis, PI. fosfomycin: use beyond urinary tract and
gastrointestinal infections. Clin Infect dis 2008 ; 46(7) :
1069-77.
67. falagas, ME; Roussos, n; gkegkes, Id; Rafailidis, PI;
karageorgopoulos, dE. fosfomycin for the treatment
of infections caused by gram-positive cocci with ad-
vanced antimicrobial drug resistance: a review of mi-
crobiological, animal and clinical studies. Expert opin
Investig drugs 2009; 18(7): 921-44.
68. legat, fJ; Maier, a; dittrich, P; zenahlik, P; et al. Pen-
etration of fosfomycin into Inflammatory lesions in
Patients  with  Cellulitis  or  diabetic  foot  Syndrome. 
antimicrob  agents  Chemother  2003;  47(1):  371-
374.
69. durupt S, Josserand Rn, Sibille M, durieu I. acute, re-
current  fosfomycin-induced  liver  toxicity  in  an  adult
patient with cyctic fibrosis. Scand J Infect dis 2001;33:
391-2
70. Eliopoulos gM. Quinopristin-dalfopristin and linezol-
id: evidence and opinion. Clin Infect dis 2003;36:473-
481
71. Raad I, Hachem R, Hanna H, afif C et al. Prospective,
randomized study comparing quinopristin-dalfopristin
with linezolid in the treatment of vancomycin-resistant
Enterococcus  faecium  infections.  J  antimicrob
Chemother 2004;53:646-649
72. Paterson  dl.  Clinical  experience  with  recently  ap-
proved antibiotics. Curr opin Pharmacol 2006;6:485-
490
73. barnes EV, dooley dP, Hepburn MJ, baum SE. out-
comes  of  community-acquired,  methicillin-resistant
Staphylococcus  aureus,  soft  tissue  infections  treated
with antibiotics other than vancomycin. Mil Med 2006;
171:504-507
74. Hyun  dy,  Mason  Eo,  forbes  a,  kaplan  Sl.
Trimethoprim-sulfamethoxazole  or  clindamycin  for
treatment  of  community-acquired  methicillin-resistant
Staphylocuccus aureus skin and soft tissue infections.
Pediatr Infect dis J. 2009;28:57-59
75. loeb M, Main C, Walker-dilks C, Eady a. Cochrane
database Syst Rev 2003;(4):Cd003340 
76. Pankey ga, Sabath ld Clinical relevance of bacterio-
static versus bactericidal mechanisms of action in the
treatment of grampositive bacterial infections. Clin In-
fect dis 2004;38:864-870
77. Szumowski  Jd,  Cohen  dE,  kanaya  f,  Mayer  kH.
Treatment and outcomes of infections by methicillin-
resistant Staphylococcus aureus at an ambulatory clinic.
antimicrob agents Chemother 2007;51:423-428
78. Stevens dl, bisno al et al. Practice guidelines for the
diagnosis and management of skin and soft tissue in-
fections. Clin Inf dis 2005; 41: 1373-1406
79. Eron lJ, lipsky ba low dE et al. Managing skin and
soft  tissue  infections:  expert  panel  recommendations
on  key  decision  points.  J  antimicrob  Chemother
2003;52 (S1:i3-17
80. gould fk, brindle R, Chadwick PR et al. guidelines
for the prophylaxis and treatment of methicillin-resis-
tant Staphylococcus aureus (MRSa) infections in the
united  kingdom.  J  antimicrob  Chemother  2009;63:
849-861
81. Eckmann C. Isenmann R, kujath P et al. Intraabdomi-
nal infections. In: bodmann kf, grabein b et al. Rec-
ommendations for calculated parenteral initial therapy
of bacterial diseases in adults – update 2010. ISbn 978-
3-00-031623-4:p46-52
EuRoPEan JouRnal of MEdICal RESEaRCH 562 november 30, 2010
6 Eckmann##_Umbruchvorlage  23.11.10  11:50  Seite 562EuRoPEan JouRnal of MEdICal RESEaRCH november 30, 2010 8, 2010 563
82. Paul M, bishara J, levcovich a et al. Effectiveness and
safety  of  colistin:  prospective  comparative  cohort
study. J antimicrob Chemother 2010;65:1019-1027
Receuved: November 2, 2010 / Accepted: November 10, 2010
Address for correspondence:
Priv.-doz. dr. med. Christian Eckmann
klinikum Peine ggmbH
academic Hospital of Medical university Hannover
Virchowstrasse 8h
31226 Peine
germany
Phone: +49/(0)5171/931530
fax: +49/(0)5171/931549
E-mail: christian.eckmann@klinikum-peine.de Christian Eckmann
6 Eckmann##_Umbruchvorlage  23.11.10  11:50  Seite 563